Assessing genetic risk factors for Alzheimer's disease
Official title: Leveraging high-throughput functional data for assessment of Alzheimer's risk
Funded at Constantiam Biosciences INC. · NIH-10919316 · Data updated 2026-11-12
This study is looking at how our genes might affect the risk of Alzheimer's and similar conditions, and it's creating a new app called MAVEvidence to help identify individual risk levels, so people can get personalized care and support earlier.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Constantiam Biosciences INC. NIH-funded |
| Lab location | 1 site (Katy, United States) |
| Project start | September 20, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $485,192 |
| NIH project number | 1R43AG084431-01A1 |
| Project ID | NIH-10919316 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with a family history of Alzheimer's disease or those who are concerned about their genetic risk for developing the condition.
✕Less likely to help
Patients who do not have a genetic predisposition to Alzheimer's disease or related dementias may not benefit from this research.
What this research studies
This research focuses on understanding the genetic factors that contribute to Alzheimer's disease (AD) and related dementias (ADRD). It aims to improve early risk assessment and screening by developing a new application called MAVEvidence, which uses advanced assays to analyze thousands of genetic variants in proteins associated with AD. By identifying and classifying these variants, the research seeks to provide better insights into individual risk levels, potentially leading to more personalized management strategies for those at risk. The study emphasizes the importance of early intervention in the progression of these irreversible brain disorders.
Why it matters
Potential benefit: If successful, this research could lead to more accurate risk assessments for Alzheimer's disease, enabling earlier interventions and personalized treatment plans.
How similar studies have gone: Other research has successfully utilized similar genetic assessment approaches in cardiovascular and cancer risk, suggesting potential for success in Alzheimer's disease as well.
Where this research is happening
-
Constantiam Biosciences INC.
Katy, United States Active
Researchers
- Principal investigator: Schafer, Nicholas — Constantiam Biosciences INC.
- Study coordinator: Schafer, Nicholas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.